Evaluating Early Treatment Response in CML: Expert Insights on Monitoring

Panelists discuss how in standard clinical practice, response to first-line tyrosine kinase inhibitor therapy is monitored through regular molecular testing of BCR::ABL1 transcript levels, with key evaluations to assess whether patients achieve target milestone responses that predict long-term outcomes.

Now Viewing

EP: 1.Evaluating Early Treatment Response in CML: Expert Insights on Monitoring

Video content above is prompted by the following:

• The NCCN guidelines had recent updates for evaluating early treatment response milestones. In a patient on first-line tyrosine kinase inhibitor, how do you monitor and evaluate response in your clinical practice?

Related Videos